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available in Brazil for preventing skeletal events (SE) in breast
cancer patients with bone metastasis. METHODS: Indirect
comparison of different clinical trials published do not allow us
to consider that exist an efﬁcacy difference among ibandronate
acid, zoledronic acid and pamidronic acid (e.g.: Body et al.
2004; Rosen et al. 2003; Theriault et al. 1999). In our analysis
only direct costs were considered. The indirect costs of treating
SE were not estimated. For direct costs calculations we assumed
the reduction in analgesics usage reported by De Cock et a.
2005 (Ibandronic acid: 7% reduction vs. Comparators: 3%
reduction). The time horizon of the analysis was 14 months
which represents the average overall survival of patients
(Hotton J et al. 2004). Therefore discounting was not applied.
The payer perspective was adopted under the Brazilian setting.
A one-way sensitivity analysis was conducted. RESULTS:
Results show that ibandronic acid offers the lowest treatment
cost, followed by pamidronic acid and zoledronic acid (R$
10,301, R$ 10,906 and R$ 12,829). Results were sensitive to
drug prices. CONCLUSION: Results suggest ibandronate acid
as a cost-saving alternative with better safety proﬁle when com-
pared to zoledronic acid and pamidronic acid under the Private
Healthcare System perspective in Brazil.
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OBJECTIVES: Navelbine® (Vinorelbine) Oral is an orally
administered formulation of chemotherapy (CT) recently intro-
duced in Italy in the treatment of NSCLC (Non Small Cell Lung
Cancer) and Metastatic Breast Cancer. The purpose of this study
is to evaluate the economic consequences of the impact on phar-
macy, nursing time and patient waiting time of a switch from IV
to oral CT in the treatment of NSCLC. METHODS: Cost-
minimisation analysis was developed in order to evaluate the
times required to deliver IV vinorelbine and oral vinorelbine. The
comparison was made in two settings with different patient path-
ways, in the Cancer Center Unit of Istituto Nazionale dei Tumori,
Milan and Azienda Ospedaliera di Busto Arsizio, Varese. A stop-
watch was used to time elements of essential processes (phar-
macy preparation and chemotherapy administration) and patient
waiting time for the delivery of a single dose of chemotherapy, in
order to build an hypothetic diagnostic and therapeutic pathway
and to describe different phases, times and costs for each formu-
lation. RESULTS: Administration of Vinorelbine Oral was less
time consuming in both Cancer Centres. In the base case sce-
nario, total costs were €171.75 for Oral Vinorelbine (60 mg/m2)
versus €214.84 for IV Vinorelbine (25 mg/m2); for Oral Vinorel-
bine (80 mg/m2) versus IV Vinorelbine (30 mg/m2) costs were
€240.46 and €232.82 respectively. Productivity loss and patient
waiting time were key drivers to our cost minimisation analysis.
Results were submitted to a Sensitivity Analysis. CONCLU-
SION: Delivery of oral CT is less resource intensive and time
consuming than IV CT and reduces overall patient waiting in
hospital. A switch from Vinorelbine IV to Oral formulation with
home administration could increase the capacity of the Day-
Hospital Unit, the number of prescriptions prepared by phar-
macy and thereafter a reduction of the patient waiting list wich is
associated with a global cost reduction.
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OBJECTIVES: The purpose of this study was to compare the
costs of the drug, drug administration and managing of adverse
events (AEs) using erlotinib, docetaxel and pemetrexed as second
line therapy in non-small cell lung cancer (NSCLC), in the Italian
hospital setting. METHODS: Since a clinical study comparing
the three therapies is not available, the major clinical ﬁndings
from randomized trials of each drug were used showing that all
three chemotherapies have comparable efﬁcacy results. Therefore
a cost-minimization analysis was performed. Costs from the
hospital perspective were calculated according to Italian clinical
practice. Consumption of each chemotherapy was based on
respective clinical trial, while to estimate the resources used in the
AEs and for the drug administration a Delphi panel of experts
was structured. In order to allow a comparison between an oral
daily therapy (erlotinib) and infusion therapies administered
every 21 days (docetaxel and pemetrexed), costs were computed
on a monthly base. RESULTS: The total per-patient cost for
erlotinib was €1669, €2569 for docetaxel and €3324 for pemetr-
exed for one month therapy from the hospital perspective. The
cost of AEs represents the 8%, 18%, and 3% of the total cost for
erlotinib, docetaxel and pemetrexed. Sensitivity analysis showed
that no reasonable changes in the quantity and cost of services
reduced the savings associated with erlotinib by more than 33%.
CONCLUSION: A cost-minimization analysis was performed to
assess the cost of three second line chemotherapies in non-small
cell lung cancer. The less costly alternative was erlotinib which
could produce savings between 40% anD 50% of total hospital
costs in Italy.
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OBJECTIVES: To value the use of resources and costs linked
with different presentations of oxaliplatin: lyophilised powder
and concentrated solution. METHODS: A cost-minimization
analysis was conducted with the Spanish hospital’s perspective.
Time consumption and use of resources linked with the prepa-
ration of the products were obtained from a study conducted in
a cancer center in France. The preparation was performed
according to standard clinical practice and several measures were
taken to avoid any bias in the process. Spanish unitary costs were
applied to all resource measures: technicianxs time, consumables
(needles, syringes, water, tampon gauze and air intake), using
cost data from a Spanish oncology centre. RESULTS: The new
concentration solution of oxaliplatin achieves a 56% reduction
in preparation time, saving 139 seconds compared with the lyo-
philised powder (p < 0.001) and also is linked to less use of
consumables. Monetary savings linked to preparation time and
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